Heterocyclic-Modified Imidazoquinoline Derivatives: Selective TLR7 Agonist Regulates Tumor Microenvironment against Melanoma-Reference-Cited by-同舟云学术

Heterocyclic-Modified Imidazoquinoline Derivatives: Selective TLR7 Agonist Regulates Tumor Microenvironment against Melanoma

Published:2024-02-16 Issue:5 Volume:67 Page:3321-3338
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Ou Jiaxin¹,Zheng Lu¹,Chen Yanlin¹,Fu Qiuyue¹,Tan Liyi¹,Liang En¹,Huang Lan¹,Pan Yue¹,Ke Jiahua¹,Chen Zhipeng¹,Cheng Kui¹^ORCID

Affiliation:

1. Guangdong Provincial Key Laboratory of New Drug Screening, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism and Guangdong-Hong Kong-Macao Joint Laboratory for New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China

Funder

Ministry of Science and Technology of the People's Republic of China

National Natural Science Foundation of China

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c01504

Reference40 articles.

1. The expanding role for small molecules in immuno-oncology

2. Immune checkpoint signaling and cancer immunotherapy

3. Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics

4. Toll-like receptor-induced cytokines as immunotherapeutic targets in cancers and autoimmune diseases

5. Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploration of 1-(indolin-1-yl)-2-(thiazol-2-yl)ethan-1-one derivatives as novel anti-HBV agent with potential TLR7-agonistic effect;European Journal of Medicinal Chemistry;2024-09

2. Design and Synthesis of Polyphenolic Imidazo[4,5-c]quinoline Derivatives to Modulate Toll Like Receptor-7 Agonistic Activity and Adjuvanticity;ACS Pharmacology & Translational Science;2024-06-12

3. Design, Synthesis, and Biological Evaluation of New 2,6,7-Substituted Purine Derivatives as Toll-like Receptor 7 Agonists for Intranasal Vaccine Adjuvants;Journal of Medicinal Chemistry;2024-05-24

4. Structure–Activity Relationships toward the Identification of a High-Potency Selective Human Toll-like Receptor-7 Agonist;Journal of Medicinal Chemistry;2024-05-14